Ignite Creation Date:
2025-12-25 @ 4:23 AM
Ignite Modification Date:
2026-06-13 @ 6:31 AM
Study NCT ID:
NCT02517320
Status:
COMPLETED
Last Update Posted:
2017-03-03
First Post:
2015-08-04
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy
Sponsor:
Tanabe Pharma Corporation
Organization:
Study Overview
Official Title:
A Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy
Status:
COMPLETED
Status Verified Date:
2017-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the efficacy of MT-3995 in subjects with diabetic nephropathy, compared with placebo, using urine albumin- to-creatinine ratio (UACR) in the first morning void urine sample as an indicator.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: